

FiberTape[®] Sternal Closure

SIMPLE. TENSIONABLE. PRECISE.



SCAN ME to learn
more about this
innovative product

Arthrex[®] 

FiberTape[®] Sternal Closure

SIMPLE. TENSIONABLE. PRECISE.

Low-Profile Design

- Flat construct allows for plating over tapes, if necessary
- Tucking the knot stack to the side of the sternum may help minimize soft-tissue irritation

Zero Metal – 100% Suture Material


- Easy to remove, if necessary; can be cut out simply with a knife blade
- No sharp metal ends to potentially harm the surgical staff or irritate the patient
- Radiolucent; no metal artifact on x-ray

Tension With Confidence

- Tensioner delivers controllable and reproducible compression



FiberTape cerclage
reusable tensioner



Arthrex[®] 

Value Proposition

History of Clinical Success

- Comprised of UHMWPE and polyester weave, the FiberTape implant has more than 10 years of clinical success in multiple orthopedic applications

Mechanical Properties

- Offers strong fixation and rigid stabilization
- Rigid enough to ensure stabilization but possibly elastic enough for micromotion to aid in secondary bone healing

Broad Footprint Compression

- May help reduce bone cut-through



SCAN ME to learn
more about this
innovative product





FiberTape cerclage
disposable tensioner


Metal wires are a thing of the past. FiberTape sternal closure is the fixation technology of the future.

FiberTape sternal closure is a 100% nonmetallic, radio-lucent alternative to stainless steel wires traditionally used for sternal closure procedures. For more than a decade, the FiberTape implant—which is composed of UHMWPE and polyester weave—has been used successfully in multiple orthopedic applications. With its high-strength, all-suture design and bio-mechanical properties, FiberTape sternal closure meets the demands of sternotomy fixation.

The FiberTape sternal closure system is engineered for easy incorporation into cardiothoracic procedures. Pass the sutures in a familiar simple interrupted and/or figure-eight stitch configuration. Once passed, tighten each suture with the unique tensioning device for controlled compression and precise sternal approximation.



Stronger Than Conventional Methods¹
Load-to-Failure Comparison




10+ YEARS
For more than a decade, FiberTape suture has been used for multiple fixation applications in orthopedics


1. Arthrex, Inc. Data on file (APT 5056). Naples, FL; 2021.

ZIPFIX is a registered trademark of DePuy Synthes.


Surgical Steps



1 Begin by placing a simple interrupted stitch in the manubrium.



2 After all the sutures are passed, shuttle the FiberTape suture tails through the pretied knot on their respective loaders.



3 Place the tensioner against the knot and turn the handle to begin tensioning. Continue turning the handle to remove slack from the sutures and until an appropriate amount of tension is achieved.



4 Once the desired amount of compression is achieved and the sternal edges are approximated, tie two alternating half-hitches on top of each knot to lock and secure the FiberTape sternal closure constructs.



We are Arthrex.

We're a global medical device company and a leader in new product development since 1981. Our corporate mission shapes our ideas and innovations: **Helping Surgeons Treat Their Patients Better.**

We are strategically focused on constant product innovation through scientific research, surgeon collaboration, and medical education to make less invasive surgical procedures simple, safer, and more reproducible. Each year, we develop more than 1000 new innovative products and procedures to advance minimally invasive orthopedics worldwide. Arthrex has always remained a privately held company, which allows

for the rapid evaluation of new technologies and ideas and the freedom to develop products and techniques that truly make a difference. Our experienced team of dedicated professionals represents a shared passion and commitment to delivering uncompromising quality to the health care providers who use our products and the millions of patients whose lives we impact.

The medical significance of our contributions serves as our primary benchmark of success and will continue into the future as the legacy of Arthrex.



This description of technique is provided as an educational tool and clinical aid to assist properly licensed medical professionals in the usage of specific Arthrex products. As part of this professional usage, the medical professional must use their professional judgment in making any final determinations in product usage and technique. In doing so, the medical professional should rely on their own training and experience and should conduct a thorough review of pertinent medical literature and the product's directions for use. Postoperative management is patient-specific and dependent on the treating professional's assessment. Individual results will vary and not all patients will experience the same postoperative activity level or outcomes.



Arthrex Manufacturer, Authorized Representative and Importer information: eIFU - Arthrex



US patent information

arthrex.com    

© 2023-09 Arthrex GmbH. All rights reserved. FL2-000707-en-US_A



Helping Surgeons Treat Their Patients Better[®]

by improving sternotomy outcomes with biologics

Prevent Infections^{1,2,3}

- Although advancements in treating deep sternal wound infections have decreased patient mortality, deep sternal wound infection incidents have remained unchanged since the 1980s
- PRP application prior to surgical wound closure reduces the incidence of deep and superficial wound infections after medial sternotomy

Reduce Costs

- Post-surgical wound infections can occur up to 4 months after surgery and are related to high costs
- Patients who received surgical wound care treatment with PRP accounted for significantly reduced post-surgical treatment costs



Arthrex ACP[®]

- Fast point-of-care PRP production
- Closed system for increased safety



ACP Max[™]

- 2-step PRP production system for defined output volumes
- Highest increase of thrombocyte-related growth factor



Thrombinator[™]

- Production of all-autologous fibrin matrix

1. Patel, Amit N et al. "Evaluation of autologous platelet rich plasma for cardiac surgery: outcome analysis of 2000 patients." *Journal of cardiothoracic surgery* vol. 11,1 62. 12 Apr. 2016, doi:10.1186/s13019-016-0452-9

2. Serraino, Giuseppe F et al. "Platelet-rich plasma inside the sternotomy wound reduces the incidence of sternal wound infections." *International wound journal* vol. 12,3 (2015): 260-4. doi:10.1111/iwj.12087

3. Gallo I, et al. Autologous Platelet-rich Plasma: Effect on Sternal Healing in the Sheep Model. *Interactive CardioVascular and Thoracic Surgery*. 2010;11(3):223-5.